{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:50:50Z","timestamp":1773694250833,"version":"3.50.1"},"reference-count":31,"publisher":"ALUNA","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>The aim: Evaluating the role SNP rs351855 of (FGFR4) gene and estimating the serum concentration of Visfatin cytokine and (HMGB-1) protein in AC patients and in healthy control blood samples. \nMaterials and methods: Blood samples were collected from 35 patients and 35 healthy controls, and then the serum was used for ELISA test, another each 2 ml blood were used for DNA extraction and rs351855 of (FGFR4) PCR assay. \nResults: there was no significant difference in mean HMG and mean visfatin among (FGFR4) rs351855 genotypes in patients and control group. There was no significant difference in mean (HMG) among (FGFR) rs351855 genotypes in patients` group (p = 0.923); there was also no significant difference in mean visfatin among FGFR rs351855 genotypes in patients` group (p=0.161) rs351855 genotypes showed that the homozygous GG, heterozygous A\/G and homozygous AA. Despite these minor differences there was no significant variation (p = 0.323), also no significant difference in frequency distribution of individuals according to FGFR rs351855 G&gt;A SNP polymorphism between patients` and control groups (p = 0.454). The same was applied to recessive and allelic analysis p&gt;0.05. \nConclusions: There was no role for (FGFR4) rs351855G\/A SNP in disease susceptibility to acute cholecystitis in Iraqi patients. Visfatin cytokine and HMGB-1 protein might act as a good biomarker for diseases.<\/jats:p>","DOI":"10.36740\/wlek202205203","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:37:02Z","timestamp":1656344222000},"page":"1242-1247","source":"Crossref","is-referenced-by-count":1,"title":["IMPACT OF FGFR4 (GLY388ARG) GENE POLYMORPHISM ALONG WITH VISFATIN CYTOKINE AND HIGH MOBILITY GROUP BOX-1 (HMGB1) ON ACUTE CHOLECYSTITIS"],"prefix":"10.36740","volume":"75","author":[{"given":"Israa H.","family":"Alfuaadi","sequence":"first","affiliation":[{"name":"UNIVERSITY OF AL-QADISIYAH, AL DIWANIYAH, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim A.","family":"Altamemi","sequence":"additional","affiliation":[{"name":"UNIVERSITY OF AL-QADISIYAH, AL DIWANIYAH, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Dai Y., Arellano R.S. Current Status of Percutaneous Cholecystectomy for the Management of Cholecystitis. Dig Dis Interv. 2017; 1(01): 22-7.","DOI":"10.1055\/s-0037-1599274"},{"key":"ref1","unstructured":"2. Ralston S.H., Penman I.D., Strachan M.W.J., Hobson R. Davidson\u2019s Principles and Practice of Medicine E-Book. Elsevier Health Sciences. 2018."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Adachi T., Eguchi S., Mutoh Y. Pathophysiology and pathology of acute cholecystitis; A secondary publication of the Japanese version in 1992. J Hepato\u2013Biliary\u2013Pancreatic Sci. 2021.","DOI":"10.1002\/jhbp.912"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Cuevas A., Miquel J.F., Reyes M.S. et al. Diet as a risk factor for cholesterol gallstone disease. J Am Coll Nutr. 2004; 23(3): 187-96.","DOI":"10.1080\/07315724.2004.10719360"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Ansaloni L., Pisano M., Coccolini F. et al. WSES guidelines on acute calculous cholecystitis. World J Emerg Surg. 2016; 11(1): 1-23.","DOI":"10.1186\/1749-7922-9-58"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Knab L.M., Boller A-M., Mahvi D.M. Cholecystitis. Surg Clin. 2014; 94(2): 455-70.","DOI":"10.1016\/j.suc.2014.01.005"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Li J-P., Huang H-C., Yang P-J. et al. FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan. Int J Environ Res Public Health. 2020; 17(16): 5694.","DOI":"10.3390\/ijerph17165694"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Tilg H., Moschen A.R. Role of adiponectin and PBEF\/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 2008; 114(4): 275-88.","DOI":"10.1042\/cs20070196"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Park J.W., Kim O.H., Lee S.C. et al. Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis. Ann Surg Treat Res. 2020; 99(1): 26-36.","DOI":"10.4174\/astr.2020.99.1.26"},{"key":"ref9","unstructured":"10. Amini M., Pakdaman A., Shapoori S., Mosayebi G. High mobility group box-1 (HMGB1) protein as a biomarker for acute cholecystitis. Reports Biochem Mol Biol. 2019; 7(2): 204."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Wang J., Yu W., Cai Y. et al. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia. 2008; 10(8): 847-56.","DOI":"10.1593\/neo.08450"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Escart\u00edn A., Gonz\u00e1lez M., Cuello E. et al. Acute cholecystitis in very elderly patients: disease management, outcomes, and risk factors for complications. Surg Res Pract. 2019.","DOI":"10.1155\/2019\/9709242"},{"key":"ref12","unstructured":"13. Jones M.W., Genova R., O\u2019Rourke M.C., Carroll C. Acute Cholecystitis. Nursing. 2021."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Yokoe M., Takada T., Strasberg S.M. et al. TG13 diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepato biliary Pancreat Sci. 2013; 20(1): 35-46.","DOI":"10.1007\/s00534-012-0568-9"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Botaitis S., Polychronidis A., Pitiakoudis M. et al. Does gender affect laparoscopic cholecystectomy? Surg Laparosc Endosc Percutaneous Tech. 2008; 18(2): 157-61.","DOI":"10.1097\/sle.0b013e318165c899"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Sangma M.M.B., Marak F. Clinicoetiopathological studies of acute cholecystitis. Int Surg J. 2016; 3(2): 914-20.","DOI":"10.18203\/2349-2902.isj20161167"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Littlefield A., Lenahan C. Cholelithiasis: presentation and management. J Midwifery Womens Health. 2019; 64(3): 289-97.","DOI":"10.1111\/jmwh.12959"},{"key":"ref17","unstructured":"18. Shabanzadeh D.M. New determinants for gallstone disease. Dan Med J. 2018; 65(2): B5438."},{"key":"ref18","unstructured":"19. Ortona E., Pierdominici M., Maselli A. et al. Sex-based differences in autoimmune diseases. Ann 1st Super Sanita. 2016; 52(2): 205-12."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Banim P.J.R., Luben R.N., Bulluck H. et al. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk). Eur J Gastroenterol Hepatol. 2011; 23(8): 733-40.","DOI":"10.1097\/meg.0b013e3283477cc9"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Erlandson H., Anderson U. The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004; 34: 1503-12.","DOI":"10.1002\/eji.200424916"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Kim H.M., Kim Y-M. HMGB1: LPS delivery vehicle for caspase-11- mediated pyroptosis. Immunity. 2018; 49(4): 582-4.","DOI":"10.1016\/j.immuni.2018.09.021"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Samara A., Pfister M., Marie B., Visvikis\u2013Siest S. Visfatin, low\u2013grade inflammation and body mass index (BMI). Clin Endocrinol (Oxf). 2008; 69(4): 568-74.","DOI":"10.1111\/j.1365-2265.2008.03205.x"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Moschen A.R., Kaser A., Enrich B. et al. Visfatin, an adipocytokines with proinflammatory and immunomodulating properties. J Immunol. 2007; 178(3): 1748-58.","DOI":"10.4049\/jimmunol.178.3.1748"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Meier F.M.P., Frommer K.W., Peters M.A. et al. Visfatin\/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem. 2012; 287(34): 28378-85.","DOI":"10.1074\/jbc.m111.312884"},{"key":"ref25","unstructured":"26. Al-Helfy S.H.A., Almayah Q.S., Allami R.H. Cholelithiasis following bariatric surgery: a new approach to deal with. IRAQI J Med Sci. 2017; 15(2): 143-50."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Chen Q., Li W.J., Wan Y.Y. et al. Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population. Genet Mol Res. 2012; 11(1): 548-55.","DOI":"10.4238\/2012.march.8.3"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Botea F., Kraft A., Popescu I. Pathophysiology and Diagnosis of Acute Calculous Cholecystitis. In: Difficult Acute Cholecystitis. Springer. 2021, 32\u0440.","DOI":"10.1007\/978-3-030-62102-5_3"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Abdeldayem H. Updates in Gallbladder Diseases. BoD\u2013Books on Demand. 2017.","DOI":"10.5772\/65176"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Lee S.P., Carey M.C., LaMont J.T. Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science. 1981; 211(4489): 1429-31.","DOI":"10.1126\/science.7466399"},{"key":"ref30","unstructured":"31. Stone W.L., Basit H., Burns B. Pathology, Inflammation. Stat Pearls. 2019."}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:37:13Z","timestamp":1656344233000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2022\/05\/WLek202205203.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202205203","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}